- IPO date: November 8, 2021
- Denomination: MaaT Pharma
- ISIN code/ticker: FR0012634822 / MAAT
- ICB classification: 20103010 – Biotechnology
- Listing market: Euronext Paris regulated market
- Eligible for the PEA and PEA-PME schemes and for the 150-0 B ter scheme of the CGI
- Analysts covering the share:
- KBC Securities: Thomas Vranken & Jeroen Van den Bossche
- Kempen: Suzanne van Voorthuizen & Luísa Morgado
- Kepler Cheuvreux: Clémence Thiers & Arsene Guekam
- Portzamparc Groupe BNP Paribas: Mohamed Kaabouni
Building a leading microbiome company in oncology
We are the first company developing microbiome-based drugs listed on the regulated market of Euronext Paris.
Stock information
Download our corporate presentation
Board of Directors
Jean-Marie has been President and CEO of Biocodex. He steered the creation of the “Biocodex Microbiota Institute” supporting innovative projects from Microbiota researchers. Jean-Marie has a long-track record of CEO positions amongst international firms such as LVMH or Bongrain.
Engineering degree Ecole Centrale Paris, MBA from Insead
Jean Volatier is a graduate of the Magistère en Sciences de Gestion de l'Universtité Paris IX Dauphine (PSL), of the D.E.S.C.F. and of the Master en Executive Mangement Globale RSE de Mines Paris Tech (PSL) and is an independent director on the Board of Directors. Jean Volatier is currently CFO at Inventiva. Prior to that, he started his career at Pricewaterhouse Coopers in Paris and Philadelphia. He then moved to different positions in the Finance Department, first at Laboratoires URGO Soins & Santé and then internationally at Laboratoires Fournier, before holding different positions as CFO at the Soufflet and NAOS groups.
CFO
Claude joined MaaT Pharma as an independent board member in July 2020. Since 2017, Claude has held the position of Executive Vice President of R&D and Chief Scientific Officer at Servier. He brings decades of high-level leadership in pharmaceutical R&D, having previously served as Executive Vice-President of R&D at Ipsen Pharma and as Global Senior Vice President for Respiratory & Inflammation Research Area at AstraZeneca. His career also includes senior positions at Novartis, Roche and Pfizer.
PharmD, PhD
Dorothée Burkel holds a Master's degree from the Institut d'Etudes Politiques in Paris and is an independent director on the board of Directors. She is also Director of Human Resources, Information Systems and Communication and a member of the Executive Committee of PartnerRe. She brings decades of high-level experience in human resources and communication, having participated in the transformation of companies at an international level in the new technology and financial sectors.
She was formerly HR Director EMEA at Google and HR Director France at AOL.
She was formerly HR Director EMEA at Google and HR Director France at AOL.
Chief Corporate and People Operations Officer
Isabelle de Crémoux is CEO and Managing Partner of Seventure Partners and leads the Life Sciences team. She joined Seventure in 2001 to establish the Life Sciences division. Isabelle supervises the Life Sciences business and personally invests in French and Scandinavian and north American biotech, nutrition, healthcare, personalized medicine. Isabelle has a particular interest in the microbiome field and frequently gives lectures at conferences in this domain. As a visionary, she launched Health for Life Capital™, the first European investment vehicule to support the microbiome revolution. Prior to joining Seventure Partners, she worke at Arthur Andersen/ EY, Pfizeer and Laboratoires Fournier.
Engineering degree from Ecole Centrale Paris
Muriel Prudent is an Investor at Bpifrance, French public investment bank, managing a portfolio of health- and other deeptech startups within the PSIM Fund, which focuses on major tech disruptions.
Graduated from HEC Paris and Bocconi University in Milan
Graduated from HEC Paris and Bocconi University in Milan
Hervé Affagard is the CEO and founder of MaaT Pharma. For the past 15 years, Hervé has been an intra/entrepreneur in the healthcare industry, after starting his career in IT in the steel industry. He founded MaaT Pharma in late 2014 together with onco-hematologist Prof. Mohammad Mohty and microbiologist Dr. Joël Doré, after a professional career that spanned multiple industries. Hervé has led MaaT Pharma’s development from its early concept in 2013 and has been at the forefront of the development of the microbiome healthcare ecosystem in France and Europe. Hervé is also a board member for the French biotech industry association, France Biotech and an active contributor to Allliance Promotion Microbiote, an organization recently founded to support the microbiome sector development in France.
Engineer, MBA,
Events & Presentations
2023
- January 2023 – Corporate Presentation
2022
- December 12, 2022 – Investor webcast ASH congress
- June 07, 2022 – R&D Day
- January 10-13, 2022 – H.C Wainwright Bioconnect 2022 Conference replay
- 2022 – Operation Note
2021
December, 13 2021 – Investors Webcast – Corporate Update
2021 – Financial Annual Report – Only in French
Regulated information
2022
- 2022 – Half Year Financial Report – Only in French
- 2022 – Universal Registration Document – Only in French
- May 31, 2022 – Information on the compensation of corporate officers
- February 09, 2022 – Number of shares and voting rights – Only in French
- January 26, 2022 – Number of voting rights
- January 03, 2022 – Number of shares and voting rights – Only in French
2021
2021 – Registration Document
General Meetings
May 31, 2022
Annual Combined General Meeting documents
- Minutes of the annual combined general meeting – Only in French
- April 25, 2022 – Number of voting rights
- Notice of meeting BALO announcement – Only in French
March 3, 2022
Combined General Meeting - (ordinary & extraordinary)
- Minutes of the combined general meeting (ordinary and extraordinary) – Only in French
- Auditors’ reports on the share capital decrease – Only in French
- Ordinary and extraordinary Shareholders’ General Meeting – Press Release
- Notice of meeting to the ordinary and extraordinary General Meeting – Only in French
Provisional financial calendar*
2023
- March 30 – Publication Annual Results
- April 26 – Calling Annual General Meeting
- May 9 – Revenues and Cash Position Quarter 1
- June (TBD) – Annual General Meeting
- July 27 – Revenues and Cash Position Quarter 2
- September 26 – Half-Year Results 1
- November 9 – Revenues and Cash Position Quarter 3
*Indicative calendar could be subject to change.
Investor contact
MaaT Pharma
70 avenue Tony Garnier
69007 Lyon
Email: invest@maat-pharma.com
Phone: +33 (0) 4 28 29 14 00
Hervé Affagard
CEO and co-founder
Siân Crouzet
Chief Financial and Operations Officer
